your doctor should review all current medicines [16] [17] Realistic expectations for weight loss , including the likelihood of weight regain if treatment is discontinued a pattern observed with other medicines in this class Long-term commitment and monitoring requirements , including regular blood tests (including renal function, HbA1c, and liver enzymes), cardiovascular assessments, and follow-up appointments Pregnancy, breastfeeding, and contraception : Weight-loss medicines are not recommended during pregnancy or breastfeeding
Advances and next-generation incretin therapies The expansion of this class of medications is moving rapidly, and this is likely just the beginning
The FDA may take extra time to evaluate the glucagon-related safety signals, particularly the heart rate increase (up to 6.7 bpm above baseline) and dysesthesia (Nature Medicine, 2024)
C-peptide, a peptide released from pro-insulin to generate mature insulin, is a proxy measure for insulin release
